Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Dec 15;59(7):1284-9.
doi: 10.1002/pbc.24258. Epub 2012 Jul 27.

Impact of low-dose involved-field radiation therapy on pediatric patients with lymphocyte-predominant Hodgkin lymphoma treated with chemotherapy: a report from the Children's Oncology Group

Burton E Appel  1 , Lu Chen, Allen Buxton, Suzanne L Wolden, David C Hodgson, James B Nachman
Affiliations
Clinical Trial

Impact of low-dose involved-field radiation therapy on pediatric patients with lymphocyte-predominant Hodgkin lymphoma treated with chemotherapy: a report from the Children's Oncology Group

Burton E Appel et al. Pediatr Blood Cancer. .

Abstract

Background: Treatment of pediatric lymphocyte-predominant Hodgkin lymphoma (LPHL) is controversial but has typically consisted of both chemotherapy and radiation. Radiation therapy is associated with potential late effects in children and adolescents. We examined the impact of radiation therapy on long-term outcome of patients with LPHL treated on CCG-5942, a large pediatric cooperative group study of Hodgkin lymphoma (HL).

Procedure: Eighty-two patients with LPHL were registered on CCG-5942. Fifty-two patients (63%) received chemotherapy alone; 29 patients (35%) received chemotherapy followed by involved-field radiation therapy (IFRT).

Results: The median follow-up of the LPHL patients is 7.7 years; 63 patients (77%) have >5 years of follow-up. The 5-year event-free survival (EFS) and overall survival (OS) were 97% and 100%. Two relapses occurred, both in patients who did not receive IFRT. There were no significant differences in EFS or OS between patients who received or did not receive IFRT.

Conclusions: This subset analysis demonstrates the chemosensitivity of pediatric LPHL. Patients who had a complete response to chemotherapy had an excellent EFS and OS without the addition of radiotherapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Treatment given to 82 LPHL patients on CCG-5942
Figure 2
Figure 2
Event-free survival (EFS) for 81 patients with LPHL on CCG-5942; IFRT vs. No IRFT
See this image and copyright information in PMC

References

    1. Marafioti T, Hummel M, Anagnostopoulos I, et al. Origin of nodular lymphocyte-predominant Hodgkin’s disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med. 1997;337:453–458. - PubMed
    1. Ohno T, Stribley JA, Wu G, et al. Clonality in nodular lymphocyte-predominant Hodgkin’s disease. N Engl J Med. 1997;337:459–465. - PubMed
    1. Braeuninger A, Küppers R, Strickler JG, et al. Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci USA. 1997;94:9337–9342. - PMC - PubMed
    1. Vasef MA, Alsabeh R, Medeiros LJ, et al. Immunophenotype of Reed-Sternberg and Hodgkin’s cells in sequential biopsy specimens of Hodgkin’s disease. Am J Clin Pathol. 1997;108:54–59. - PubMed
    1. Anagnostopoulos I, Hansmann M, Franssila K, et al. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: Histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood. 2000;96:1889–1899. - PubMed

Publication types